IMD business school for management and leadership courses

Novartis is integrating artificial intelligence (AI) across its operations to boost efficiency and accelerate innovation in drug development. In 2024, the company expanded AI use cases to support molecule assessment, clinical trial report automation, and drug design. In R&D, Novartis has partnered with Isomorphic Labs and Generate:Biomedicines to advance AI-enabled protein engineering and early discovery. AI also supports clinical trial optimization through advanced feasibility assessments and automation of trial reporting processes. 

On the operational front, Novartis uses its AVEVA PI System® for real-time monitoring in manufacturing, improving efficiency and ensuring product quality. The company is equally committed to responsible innovation. It has implemented a comprehensive Responsible AI framework grounded in ethical principles, transparency, and compliance oversight. Internally, Novartis has launched an enterprise-wide upskilling program – incorporating Microsoft Copilot® and a Data Science Academy – to build digital fluency and empower its global workforce.